Aptorum Group’s subsidiary Smart Pharma announces Smart Pharma token (SMPT) to be listed on IDAX and LATOKEN
Aptorum Group Limited (Nasdaq: APM) subsidiary Smart Pharmaceutical is excited to announce that the Smart Pharma Token (“SMPT token”), is to be available for trading on IDAX (https://www.idax.pro/) and LATOKEN (https://latoken.com/). IDAX and LAtoken are two leading global cryptocurrency exchange platforms. SMPT Token will commence trading on IDAX on or around July 10, 2019, and shortly thereafter on LAToken.
The SMPT token is an ERC-1404 security compliant token with ERC-20 and ERC233 compliance on the Ethereum blockchain. SMPT tokenizes rights to a portion of the royalty income derived from the eventual commercialization of intellectual property rights of drug candidates to be discovered under our Smart-ACTTM platform.
The Smart-ACTTM platform is a repurposed and new drug discovery platform launched by the Smart Pharma Group which intends to revolutionize drug discovery, repurposing and repositioning. In the forthcoming developments, Smart Pharma Group would include the incorporation of blockchain technology into the drug development and discovery processes, initially through the adoption of the SMPT token as the first step. We believe that blockchain technology will significantly increase data transparency and bring distributed power from participants worldwide to co-develop and evolve our next Smart-ACTTM platform technology.
Smart Pharma Group recognizes that blockchain-based technology will continue to play an important role in pharmaceutical development and also has the capability to foster community-based ecosystems of passionate and like-minded people in revolutionizing the drug discovery industry who would like to be an integral part of the process around projects.
Smart Pharma Community is jointly managed in collaboration with Aenco Solutions Limited. For further information, please join the discussions on our social media platforms which can be accessed as follows.
Website: https://www.smtph.com
Telegram: https://t.me/Aenco
LinkedIn: https://www.linkedin.com/company/Aenco
Medium: https://medium.com/@Aencoin
Twitter: https://twitter.com/Aencoin
Facebook: www.facebook.com/Aencoin
Discord: https://discord.gg/NXpFcKQ
YouTube: YouTube.Aencoin.com
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM) (“Aptorun”) is a pharmaceutical company dedicated to developing and commercializing a broad range of therapeutic and diagnostic technologies to tackle unmet medical needs. Aptorum Group is pursuing therapeutic and diagnostic projects in neurology, infectious diseases, gastroenterology, oncology and other disease areas as well as non-therapeutic areas such as surgical robotics and the operations of its medical clinic in Hong Kong, Talem Medical, with the initial focus on treatment of chronic diseases resulting from modern sedentary lifestyles and aging population.
For more information about Aptorum Group, please visit www.aptorumgroup.com.
About Smart Pharma Group
Smart Pharma Group includes Smart Pharmaceutical Limited Partnership, a limited partnership registered in Seychelles, and its general partner, SMTPH Limited, an international business company incorporated under the laws of Seychelles. SMTPH Limited and its subsidiaries are indirectly wholly owned by Aptorum Group Limited.
Disclaimer and Forward-Looking Statements
The SMPT tokens are currently not offered for sale to citizens, nationals, residents (tax or otherwise), green card holders and/or companies domiciled in the following: (a) the United States of America; (b) Singapore; (c) Hong Kong (except for Professional Investors); (d) the People’s Republic of China; (e) Samoa, (f) Seychelles, (g) sanctioned countries under the OFAC and (h) any other jurisdiction which prohibits the possession, dissemination or communication of the Whitepaper.
This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
Investors must rely on their own evaluation of Aptorum and its securities, including the merits and risks involved. Nothing contained herein is or shall be relied on as, a promise or representation as to the future performance of Aptorum Group or Smart Pharma group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190708005227/en/
Contact information
For Aptorum Group Limited
Investor Relations and Media
Tel: +852 2117 6611
Email: investor.relations@aptorumgroup.com
Website: http://www.aptorumgroup.com
For Smart Pharma
Information Request
Tel: +852 2117 6611
Email: info@smtph.com
Website: http://www.smtph.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ravio raises $12m Series A to modernise compensation data for global workforces8.5.2025 10:00:00 EEST | Press release
Ravio has raised a $12m Series A funding round led by Spark Capital (US) with participation from Blackbird (Australia) and Cherry Ventures (Europe) to modernise how companies manage compensation with real-time market data and decision making tools. Ravio counts leading consumer brands like Just Eat Takeaway and Octopus Energy among its customers, alongside fintech leaders such as Wise, Adyen, and Mollie. Popular tech names like Zoopla and Skyscanner have also chosen Ravio to set their compensation strategies. The compensation data gap Despite representing 70% of operating costs, most companies make these important decisions using patchy data that's 12-18 months old. This outdated approach creates significant issues: Talent leaves when underpaid compared to current market rates Companies overspend on some roles while struggling to attract talent in others Pay inequities develop as new hires and existing staff operate from different reference points "The idea for Ravio was born from runn
Celonis Recognized as a Leader for Third Consecutive Year in 2025 Gartner® Magic Quadrant™ for Process Mining Platforms8.5.2025 10:00:00 EEST | Press release
Celonis, the global leader in Process Mining and Process Intelligence, today announced that it has been named a Leader in the Gartner Magic Quadrant for Process Mining Platforms for the third time. Celonis was placed in the Leaders’ Quadrant, being positioned highest on the Ability to Execute axis and furthest on the Completeness of Vision axis once again. “We are honored to be named a Leader in the Gartner Magic Quadrant for Process Mining Platforms for the third year in a row,” said Alex Rinke, co-CEO and co-founder of Celonis. “We believe this recognition is a testament to our pioneering product innovation, our system-agnostic Process Intelligence platform, and our impressive global partner network. This recognition wouldn’t have been possible without the dedication and commitment of our customers, partners and Celonauts. Looking ahead, what excites me most is the huge potential for Celonis to enable our customers to maximize the ROI from their AI investments.” “Celonis gives us a s
Vista Equity Partners Launches VistaOne to Expand Access to Private Software Investments8.5.2025 10:00:00 EEST | Press release
Vista Equity Partners (“Vista”), a global technology investor that specializes in enterprise software, today announced the launch of VistaOne (Lux) (“VistaOne” or the “Fund”), an open-ended investment vehicle that provides eligible non-US individual investors access to Vista’s private equity platform in a single, scaled solution. The software sector has a projected 2027 total addressable market of $59 trillion and a growth rate of approximately 17%, making it the largest and fastest growing in the global economy.1 Yet approximately 96% of software companies are privately held and therefore inaccessible to most individual investors.2 VistaOne is one of the first software-specific evergreen private equity funds available to the private wealth market. Founded in 2000, Vista is an operationally focused investor that pioneered a proprietary and systematic approach to value creation developed and refined over the course of 25 years and 600+ transactions. Enterprise software touches almost ev
Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress8.5.2025 09:36:00 EEST | Press release
Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of exclusivity impact to drive revenue and Core Operating Profit growth, supported by robust cost management. Takeda has built a high-value late-stage pipeline with potentially life-transforming new treatment options for patients. Following a positive Phase 3 readout for rusfertide in Oncology in March 2025, the company anticipates a further two Phase 3 readouts in core therapeutic areas this fiscal year. FY2025 Management Guidance at CER reflects residual carry-over of VYVANSE® generic impact, continued efficiency savings and investment in R&D and launch preparation for Takeda’s late-stage pipeline. Takeda chief executive officer, Christophe Weber, commented: “Takeda delivered excellent results in FY2024. Our return to Core Operating Profit margin growth underscores the strength of our Growth & Laun
AB InBev Reports First Quarter 2025 Results8.5.2025 08:03:00 EEST | Press release
Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507671244/en/ AB InBev Strategic Priorities Regulated information1 “Beer is a passion point for consumers. The strength of the beer category and the continued momentum of our megabrands delivered another quarter of profitable growth. EBITDA increased at the top-end of our outlook and the ongoing optimization of our business drove Underlying EPS growth of 7.1%. The consistent execution of our strategy by our teams and partners drove a solid start to the year and reinforces our confidence in delivering on our outlook for 2025.” – Michel Doukeris, CEO, AB InBev Revenue +1.5% Revenue increased by 1.5% with revenue per hl growth of 3.7%. Reported revenue decreased by 6.3% to 13 628 million USD, impacted by unfavorable currency translation. 4.4% increase in combined revenues of our megabrands, led by Corona, which g
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom